CRYOPORT, INC. Equity Securities, FV-NI, Realized Gain (Loss)
CRYOPORT, INC. (CYRX) reported Equity Securities, FV-NI, Realized Gain (Loss) of -$1.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedGainLoss · last filed 2026-08-06
- CRYOPORT, INC. equity securities, fv-ni, realized gain (loss) for the quarter ending 2026-06-30 was $0.00.
- CRYOPORT, INC. equity securities, fv-ni, realized gain (loss) for the quarter ending 2026-03-31 was -$1.06M.
- CRYOPORT, INC. equity securities, fv-ni, realized gain (loss) for the quarter ending 2025-12-31 was -$157.00K.
- CRYOPORT, INC. equity securities, fv-ni, realized gain (loss) for the quarter ending 2025-09-30 was -$659.00K.
- CRYOPORT, INC. equity securities, fv-ni, realized gain (loss) for fiscal 2025 was -$203.00K.
- CRYOPORT, INC. equity securities, fv-ni, realized gain (loss) for fiscal 2024 was -$3.37M.
- CRYOPORT, INC. equity securities, fv-ni, realized gain (loss) for fiscal 2023 was -$3.76M.
- CRYOPORT, INC. equity securities, fv-ni, realized gain (loss) for fiscal 2022 was -$11.41M.
| Period end | Equity Securities, FV-NI, Realized Gain (Loss) 3 month | Equity Securities, FV-NI, Realized Gain (Loss) 6 month | Equity Securities, FV-NI, Realized Gain (Loss) 9 month | Equity Securities, FV-NI, Realized Gain (Loss) 9 month as first filed | Equity Securities, FV-NI, Realized Gain (Loss) 12 month | Equity Securities, FV-NI, Realized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.06M 10-Q · filed 2026-08-06 | -$1.22M derived: sum of 3 quarters · filed 2026-08-06 | -$1.88M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$1.06M 10-Q · filed 2026-05-05 | -$1.22M derived: sum of 2 quarters · filed 2026-05-05 | -$1.88M derived: sum of 3 quarters · filed 2026-05-05 | |||
| 2025-12-31 | -$157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$816.00K derived: sum of 2 quarters · filed 2026-03-05 | -$203.00K 10-K · filed 2026-03-05 | |||
| 2025-09-30 | -$659.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$46.00K 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | $613.00K 10-Q · filed 2026-08-06 | |||||
| 2024-12-31 | -$2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$2.34M derived: sum of 2 quarters · filed 2026-03-05 | -$2.69M derived: sum of 3 quarters · filed 2026-03-05 | -$3.37M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$348.00K derived: sum of 2 quarters · filed 2025-11-06 | -$1.03M 10-Q · filed 2025-11-06 | -$1.02M derived: sum of 4 quarters · filed 2026-03-05 | ||
| 2024-06-30 | -$348.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.03M 10-Q · filed 2025-08-12 | -$1.02M derived: sum of 3 quarters · filed 2026-03-05 | -$3.38M derived: sum of 4 quarters · filed 2026-03-05 | ||
| 2024-03-31 | -$678.00K 10-Q · filed 2025-05-08 | -$677.00K derived: sum of 2 quarters · filed 2026-03-05 | -$3.04M derived: sum of 3 quarters · filed 2026-03-05 | |||
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$2.36M derived: sum of 2 quarters · filed 2026-03-05 | -$3.76M 10-K · filed 2026-03-05 | |||
| 2023-09-30 | -$2.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$3.77M 10-Q · filed 2024-11-07 | ||||
| 2023-06-30 | -$1.41M 10-Q · filed 2024-08-08 | |||||
| 2022-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$2.85M derived: sum of 2 quarters · filed 2025-03-07 | -$6.50M derived: sum of 3 quarters · filed 2025-03-07 | -$11.41M 10-K · filed 2025-03-07 | ||
| 2022-09-30 | -$3.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$7.53M derived: sum of 2 quarters · filed 2023-11-09 | -$12.44M 10-Q · filed 2023-11-09 | -$13.51M derived: sum of 4 quarters · filed 2024-03-13 | ||
| 2022-06-30 | -$3.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$8.56M 10-Q · filed 2023-08-09 | -$9.63M derived: sum of 3 quarters · filed 2024-03-13 | -$9.79M derived: sum of 4 quarters · filed 2024-03-13 | ||
| 2022-03-31 | -$4.91M 10-Q · filed 2023-05-04 | -$5.99M derived: sum of 2 quarters · filed 2024-03-13 | -$6.14M derived: sum of 3 quarters · filed 2024-03-13 | -$6.03M derived: sum of 4 quarters · filed 2024-03-13 | ||
| 2021-12-31 | -$1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$1.23M derived: sum of 2 quarters · filed 2024-03-13 | -$1.12M derived: sum of 3 quarters · filed 2024-03-13 | -$1.39M 10-K · filed 2024-03-13 | ||
| 2021-09-30 | -$152.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$45.00K derived: sum of 2 quarters · filed 2022-11-04 | -$308.00K 10-Q · filed 2022-11-04 | -$186.00K derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-06-30 | $107.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$156.00K 10-Q · filed 2022-08-04 | -$34.00K derived: sum of 3 quarters · filed 2023-02-28 | $67.19K derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-03-31 | -$263.00K 10-Q · filed 2022-05-05 | -$141.00K derived: sum of 2 quarters · filed 2023-02-28 | -$39.81K derived: sum of 3 quarters · filed 2023-02-28 | $140.76K derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2020-12-31 | $122.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $223.19K derived: sum of 2 quarters · filed 2023-02-28 | $403.76K derived: sum of 3 quarters · filed 2023-02-28 | -$245.00K 10-K · filed 2023-02-28 | ||
| 2020-09-30 | $101.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $281.76K derived: sum of 2 quarters · filed 2021-11-04 | -$367.00K 10-Q · filed 2021-11-04 | -$367.01K 10-Q · filed 2020-11-06 | -$381.15K derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | $180.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$468.19K 10-Q · filed 2020-08-10 | -$482.34K derived: sum of 3 quarters · filed 2022-02-28 | -$645.54K derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-03-31 | -$648.76K 10-Q · filed 2020-05-08 | -$662.91K derived: sum of 2 quarters · filed 2022-02-28 | -$826.11K derived: sum of 3 quarters · filed 2022-02-28 | -$782.30K derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2019-12-31 | -$14.15K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$177.35K derived: sum of 2 quarters · filed 2022-02-28 | -$133.54K derived: sum of 3 quarters · filed 2022-02-28 | -$102.00K 10-K · filed 2022-02-28 | -$101.67K 10-K · filed 2020-03-10 | |
| 2019-09-30 | -$163.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$119.39K derived: sum of 2 quarters · filed 2019-11-12 | -$87.85K 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $43.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $75.35K 10-Q · filed 2019-08-09 | ||||
| 2019-03-31 | $31.55K 10-Q · filed 2019-05-09 | |||||
| 2018-12-31 | -$16.23K 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |